When was OZURDEX approved? A timeline of FDA clearances for key ophthalmological conditions
•
4 min read
OZURDEX received its initial FDA approval on June 17, 2009, specifically for treating macular edema following retinal vein occlusion. This marked the first step in a phased approval process for the sustained-release dexamethasone implant, providing a clear answer to the question of when was OZURDEX approved for its different indications.
